$37,485,000

Department of Health and Human Services·Office of Assistant Secretary for Preparedness and Response

WORK BEGAN2025-09-26·LATEST ACTION2026-03-17·SOURCEUSASPENDING·SOURCE IDCONT_AWD_75A50325F80036_7505_36F79723D0219_3600

Award description

PROCURENT OF XOFLUZA (BALOXAVIR MARBOXIL) 40MG AND 80MG TABLETS

Verbatim from USAspending.gov. Capitalization, abbreviations, and codes are unchanged.

The Buildout's read

What the model surfaced from this award

Confidence: high

In plain English

HHS procures Xofluza antivirals for pandemic preparedness and emergency stockpile.

Sub-sectors

antiviral-procurementpandemic-preparednessstrategic-national-stockpile

Why this matters

Antivirals are critical for pandemic response; signals government commitment to pharmaceutical stockpiling amid health threats.

Supply-chain signal

$37.5M order demonstrates U.S. investment in antiviral manufacturing capacity and pharmaceutical supply chain resilience.

U.S.–China competition angle

Reflects U.S. priority to secure domestic antiviral production for pandemic preparedness, competing with Chinese pharmaceutical manufacturing.

Generated by award_classification v2.1.0 via claude-haiku-4-5-20251001 on 2026-06-14. Cost: $0.010818.

Period of performance

Start

2025-09-26

End

2027-09-29

Status

activein 442 days

Recipient

Other awards from this recipient

Sources

USAspending.gov — all awards for this UEI →
SAM.gov entity registration →
Award record ingested from usaspending. Source identifier CONT_AWD_75A50325F80036_7505_36F79723D0219_3600.

The Buildout does not edit federal records. Any inaccuracy reflects the upstream source; it will update here when corrected there.